Amy Woodfin, PA
Physician Assistant · Mocksville, NCNPI 1609160936
Payments from drug & device makers
Across 125 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$486
- Novo Nordisk$111
- Bayer$106
- Sanofi-aventis U.S. LLC$106
- GSK$100
- Novartis$96
- plus $898 from 21 others
What the payments were for
- Food & beverage$1,903100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 41 | $486 |
| Novo Nordisk | 7 | $111 |
| Bayer | 7 | $106 |
| Sanofi-aventis U.S. LLC | 6 | $106 |
| GSK | 6 | $100 |
| Novartis | 6 | $96 |
| AbbVie | 5 | $90 |
| Boehringer Ingelheim | 5 | $82 |
| AstraZeneca | 5 | $77 |
| Dexcom, Inc. | 3 | $76 |
| Abbott | 3 | $72 |
| Lilly USA, LLC | 5 | $67 |
| Ironwood Pharmaceuticals, Inc | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| IBSA Pharma Inc. | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Amarin Pharma, Inc. | 2 | $38 |
| Shield Therapeutics Inc | 2 | $35 |
| Merck | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Exact Sciences | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Eisai Inc. | 1 | $11 |
How this compares
$1,903 in reported general payments places this provider in the 80th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 117 | $114,457 |
| JardianceEmpagliflozin | 70 | $89,519 |
| OzempicSemaglutide | 65 | $85,208 |
| MounjaroTirzepatide | 44 | $61,104 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $37,027 |
| XareltoRivaroxaban | 39 | $35,029 |
| LinzessLinaclotide | 29 | $29,560 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $28,456 |
| JanuviaSitagliptin Phosphate | 13 | $21,425 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 16 | $15,736 |
| TrulicityDulaglutide | 14 | $15,253 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $13,990 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $9,353 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,589 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $6,680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $486 | $118,043128 claims |
| Boehringer IngelheimJardiance | $82 | $89,51970 claims |
| Novo NordiskOzempic | $111 | $85,20865 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $67 | $77,85575 claims |
| GSKTrelegy Ellipta | $100 | $37,02753 claims |
| Johnson & JohnsonXarelto | $16 | $35,02939 claims |
| AbbVieLinzess, Synthroid | $90 | $31,07748 claims |
| MerckJanuvia | $34 | $21,42513 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $77 | $16,94148 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $106 | $15,73616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Mocksville
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Philip ReasbeckWilson$180K
- Katherine SchultzHuntersville$164K
- Kristin CabedaCharlotte$135K
- Jay ClarkeArden$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.